Login to Your Account



Cephalon's Oravescent Fentanyl Hits Primary Endpoint In Phase III

By Aaron Lorenzo


Friday, May 6, 2005
In reporting positive results from a Phase III study of Oravescent fentanyl, Cephalon Inc. said it is on track to submit a new drug application to the FDA next quarter. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription